Sickle cell disease (SCD) is a group of genetic disorders in which an abnormal Hb molecule (Hb S) transforms RBCs into sickle-shaped cells, resulting in chronic anemia, vasoocclusive episodes, pain, and organ damage. Sickle cell trait, which is the heterozygous condition, is the only 1 of the group that is generally benign and rarely associated with serious SCD-like complications. Triggers such as stress and hypoxia can induce or worsen the sickling of RBCs. Individuals with SCD are susceptible to infection, infarction of various organs, and bone marrow aplasia; lung involvement in acute chest syndrome can be rapidly fatal. Sickle cells can usually be seen on the peripheral blood smear, but Hb electrophoresis is needed for diagnosis. The management of painful episodes consists of IV fluids and analgesics, and in severe episodes, exchange transfusions may be required. Survival is improved by hydroxyurea intake, vaccination against bacterial infections, prophylactic antibiotics, and aggressive treatment of infections. Although trials are still ongoing and the long-term effects are still unclear, promising results from early trials show the potential for gene therapy as a treatment option.